tmem179 Antibody

What is TMEM179 and why is it studied?

Transmembrane protein 179 (TMEM179) is a 233 amino acid protein encoded by the TMEM179 gene located on chromosome 14 (14q32.33) in humans . While its function remains incompletely characterized, it is believed to play a role in the nervous system . The protein has distinctive characteristics including a predicted molecular weight of 26 kDa, an isoelectric point of 5, and notably higher levels of phenylalanine, leucine, and tryptophan compared to most proteins . TMEM179 contains four transmembrane regions with its N-terminus positioned on the cytosolic side of the membrane, and it is predicted to localize primarily to the endoplasmic reticulum . The protein exists in four different isoforms resulting from alternative splicing of the pre-mRNA transcript, making it an interesting subject for researchers studying membrane protein dynamics and neurological processes.

What applications are TMEM179 antibodies suitable for?

TMEM179 antibodies have been validated for several key applications in molecular and cellular research. Western blotting (WB) is consistently supported across available antibodies, with recommended dilution ranges typically between 1:500-1:3000 depending on the specific antibody and sample type . Immunohistochemistry (IHC) is another validated application, particularly with the Proteintech polyclonal antibody (24799-1-AP), which has been successfully used at dilutions of 1:200 on paraffin-embedded human breast cancer tissue with heat-mediated antigen retrieval using Tris-EDTA buffer (pH 9.0) . Some antibodies may also be suitable for additional applications such as ELISA, though researchers should verify the specific capabilities of their selected antibody. The choice of application should be guided by experimental goals and the performance characteristics of the specific antibody in question.

What are the optimal storage conditions for TMEM179 antibodies?

For maximum stability and longevity, TMEM179 antibodies should generally be stored at -20°C for up to one year from the date of receipt . Most commercial antibodies are formulated in stabilizing buffers - for example, the St John's Laboratory antibody (STJA0007685) is supplied as a liquid in PBS containing 50% glycerol, 0.5% BSA, and 0.02% sodium azide . It is critical to avoid repeated freeze-thaw cycles as these can significantly compromise antibody activity and specificity . Some manufacturers recommend aliquoting the antibody upon first thaw to minimize freeze-thaw events. When working with the antibody, temporary storage at 4°C is acceptable for short periods (typically 1-2 weeks), but long-term storage should always be at the recommended freezer temperature to prevent degradation of the antibody molecules.

What dilution ranges are recommended for different applications?

The recommended dilution ranges for TMEM179 antibodies vary by both application and manufacturer:

These ranges serve as starting points, and researchers should perform optimization experiments with dilution series to determine the ideal concentration for their specific samples and experimental conditions . The optimal dilution will depend on multiple factors including the abundance of the target protein, background interference from the sample matrix, and the detection system employed. For novel applications or challenging sample types, a broader dilution series (e.g., 1:100, 1:500, 1:1000, 1:2000) may be necessary to identify the optimal working concentration.

What controls should be included when validating TMEM179 antibody specificity?

Rigorous validation of TMEM179 antibody specificity requires multiple complementary controls. Positive controls should include tissues or cell lines known to express TMEM179, such as human breast cancer tissue samples which have been successfully used with the Proteintech antibody . For negative controls, samples lacking TMEM179 expression or samples where TMEM179 has been knocked down via siRNA or CRISPR-Cas9 are ideal. Additionally, peptide competition assays can be performed where the antibody is pre-incubated with the immunizing peptide before application to the sample; signal abolishment indicates specificity. Given that TMEM179 has four isoforms , researchers should be aware of which isoforms their antibody recognizes and design controls accordingly. For instance, the Santa Cruz antibody (sc-241051) is raised against an internal region of TMEM179 , and researchers should verify whether this epitope is present across all isoforms of interest.

How can researchers differentiate between the four isoforms of TMEM179?

Differentiating between the four isoforms of TMEM179 presents a significant challenge that requires careful experimental design. The isoforms vary in size and exon composition as follows:

To distinguish between these isoforms, researchers should first determine the epitope region recognized by their antibody and assess which isoforms contain this region. Western blotting with appropriate molecular weight markers can help identify isoforms based on size differences. For more definitive identification, isoform-specific primers for RT-PCR or isoform-specific siRNAs for knockdown studies can be employed. Recombinant expression of individual isoforms as positive controls is also valuable for antibody validation. The Proteintech antibody (24799-1-AP) has been tested on mouse liver tissue , while others like the recombinant protein from antibodies-online (ABIN7544284) may be useful as standards for distinguishing between isoforms .

What sample preparation techniques maximize TMEM179 detection in western blots?

Effective detection of TMEM179 in western blots begins with proper sample preparation that accounts for its nature as a multi-pass membrane protein . Cell lysis should be performed using buffers containing mild detergents like Triton X-100 or CHAPS that effectively solubilize membrane proteins while preserving native structure. For tissue samples, homogenization in the presence of protease inhibitors is crucial to prevent degradation. Since TMEM179 is predicted to localize to the endoplasmic reticulum , enrichment of membrane fractions through differential centrifugation may enhance detection sensitivity. When loading samples, avoid excessive heating (>70°C) which can cause membrane protein aggregation; instead, incubate at 37-50°C for longer periods (10-20 minutes). The Proteintech antibody protocol recommends SDS-PAGE followed by western blot with their antibody at a dilution of 1:600, incubated at room temperature for 1.5 hours . For transfer, use nitrocellulose membranes and add 0.05-0.1% SDS to the transfer buffer to facilitate efficient transfer of hydrophobic transmembrane proteins.

What are the key considerations for optimizing antigen retrieval when using TMEM179 antibodies in IHC?

Effective antigen retrieval is crucial for successful immunohistochemical detection of TMEM179, particularly in formalin-fixed, paraffin-embedded (FFPE) tissues where cross-linking can mask epitopes. The Proteintech antibody (24799-1-AP) has been validated for IHC using heat-mediated antigen retrieval with Tris-EDTA buffer at pH 9.0 , which appears to effectively expose the TMEM179 epitopes. This alkaline pH is often superior for retrieving membrane proteins compared to citrate buffer (pH 6.0). The optimal retrieval conditions may vary depending on tissue type, fixation duration, and the specific antibody used. For neuronal tissues, where TMEM179 is thought to play a functional role , researchers should be particularly careful with antigen retrieval conditions to preserve both tissue morphology and epitope accessibility. A systematic approach involving testing different retrieval buffers (citrate pH 6.0 vs. EDTA pH 8.0 vs. Tris-EDTA pH 9.0), heating methods (microwave, pressure cooker, or water bath), and durations is recommended for new tissue types or antibodies.

What approaches can resolve discrepancies in TMEM179 detection between western blot and immunohistochemistry?

Discrepancies in TMEM179 detection between western blot (WB) and immunohistochemistry (IHC) can arise from fundamental differences in epitope accessibility, protein conformation, and sample preparation between these techniques. To resolve such discrepancies, researchers should first validate antibody specificity in both applications independently. For western blot, denaturing conditions expose linear epitopes that may be inaccessible in IHC where proteins retain more of their native conformation. If an antibody works well in WB but poorly in IHC, epitope masking in the native protein may be occurring, and alternative antigen retrieval methods should be tested. Conversely, if IHC yields good results but WB does not, the epitope may be conformational and disrupted by denaturation. In such cases, non-denaturing (native) western blots might be attempted. Additionally, different isoforms of TMEM179 may show tissue-specific expression patterns, leading to apparent discrepancies between techniques. Researchers should consider using multiple antibodies targeting different regions of TMEM179 to obtain a comprehensive understanding of its expression and localization patterns across different experimental contexts.

What are effective approaches for detecting TMEM179 in the endoplasmic reticulum?

Since TMEM179 is predicted to localize to the endoplasmic reticulum (ER) , specialized approaches can enhance its detection in this compartment. Co-localization studies using established ER markers (such as calnexin, calreticulin, or KDEL-tagged proteins) provide the most definitive evidence of ER localization. For immunofluorescence, confocal microscopy with z-stack imaging allows for precise subcellular localization, while super-resolution techniques like STORM or PALM can provide even greater spatial resolution to distinguish ER subdomains. Subcellular fractionation followed by western blotting of the ER fraction can biochemically confirm TMEM179's presence in this compartment. When performing these studies, careful permeabilization is critical—gentle detergents like digitonin (0.01-0.05%) selectively permeabilize the plasma membrane while leaving the ER relatively intact, allowing for discrimination between different membrane compartments. For challenging samples, proximity ligation assays (PLA) with antibodies against TMEM179 and known ER proteins can provide sensitive detection of protein-protein interactions within the ER, potentially revealing functional associations.

How can researchers interpret variable TMEM179 antibody staining patterns in different tissues?

Variable TMEM179 antibody staining patterns across different tissues may reflect biological realities or technical artifacts that require careful interpretation. First, consider that TMEM179 exists in four isoforms , which may show tissue-specific expression patterns. The Proteintech antibody (24799-1-AP) has been validated in both human breast cancer tissue and mouse liver , potentially recognizing different isoforms in each context. Second, post-translational modifications may differ between tissues, affecting epitope accessibility. Third, protein interaction partners might mask antibody binding sites in a tissue-specific manner. To disambiguate these possibilities, researchers should employ multiple antibodies targeting different epitopes and correlate findings with mRNA expression data. Additionally, validating staining patterns through peptide competition assays or knockout controls provides confidence in observed variations. When examining neuronal tissues, where TMEM179 is thought to function , consider that specialized subcellular compartmentalization may influence staining patterns. Finally, quantitative analysis using digital pathology approaches can help objectify the assessment of staining intensity and distribution across tissues.

What troubleshooting steps should be taken when TMEM179 antibodies yield weak or no signal?

When encountering weak or absent signals with TMEM179 antibodies, a systematic troubleshooting approach is essential. First, verify antibody quality by testing positive controls known to express TMEM179. For western blots, consider loading more protein (50-100 μg total protein instead of the standard 10-30 μg) and using more sensitive detection systems like ECL-Plus or fluorescent secondary antibodies. For the Proteintech antibody, incubation at room temperature for 1.5 hours has been validated , but extending primary antibody incubation to overnight at 4°C may enhance signal. For IHC applications, optimize antigen retrieval methods beyond the standard Tris-EDTA (pH 9.0) protocol by testing different buffers, pH values, and heating times. Sample preparation is critical—ensure complete solubilization of membrane proteins using appropriate detergents, and include protease inhibitors to prevent degradation. Fresh antibody dilutions should be prepared before each experiment, as repeated freeze-thaw cycles can diminish activity . Finally, consider that TMEM179 expression levels may be naturally low in some tissues or cell types, potentially requiring signal amplification methods such as tyramide signal amplification (TSA) for detection.

How can researchers validate TMEM179 antibody specificity across species?

Validating TMEM179 antibody cross-reactivity across species requires thoughtful experimental design that accounts for sequence homology and epitope conservation. Begin with sequence alignment analysis comparing the antibody's target epitope region across species of interest. The St John's Laboratory antibody (STJA0007685) is reported to detect endogenous levels of TMEM179 in both human and mouse samples , suggesting conservation of the epitope between these species. When testing antibodies in new species, start with positive control samples from validated species alongside the test species under identical experimental conditions. Western blotting can provide preliminary evidence of cross-reactivity based on detection of proteins at the expected molecular weight (approximately 26 kDa for TMEM179 ). For definitive validation, knockdown or knockout controls in the new species provide the strongest evidence of specificity. Researchers working with non-human TMEM179 should be aware that the human and Xenopus laevis proteins share unusual amino acid compositions, including higher levels of phenylalanine, leucine, and tryptophan, as well as the conserved "LAFL" repetitive structure , which may influence antibody recognition across species.

What considerations are important when performing co-immunoprecipitation with TMEM179 antibodies?

Co-immunoprecipitation (co-IP) with TMEM179 antibodies presents unique challenges due to the protein's multi-pass transmembrane nature and ER localization . Successful co-IP requires careful buffer optimization—standard RIPA buffers may disrupt weak protein-protein interactions, so milder lysis conditions using buffers containing 0.5-1% NP-40 or digitonin with physiological salt concentrations (150 mM NaCl) are recommended for initial attempts. Pre-clearing lysates with protein A/G beads reduces non-specific binding. When selecting antibodies for co-IP, the Santa Cruz antibody (sc-241051) raised against an internal region of TMEM179 or the affinity-purified St John's Laboratory antibody (STJA0007685) may be suitable candidates, though validation for this specific application is necessary. Cross-linking antibodies to beads using dimethyl pimelimidate (DMP) prevents antibody contamination in the eluted samples. For membrane protein complexes, gentle solubilization and avoidance of harsh detergents is critical—consider using mild detergents like digitonin (0.5-1%) or CHAPS (0.5-1%). Given that TMEM179 may exist in different conformational states or complexes depending on cellular context, optimization of extraction conditions for each experimental system is essential for capturing physiologically relevant interactions.

What are emerging techniques for studying TMEM179 localization and dynamics?

Emerging technologies offer exciting opportunities to advance understanding of TMEM179 localization and dynamics beyond traditional antibody-based methods. CRISPR-Cas9 knock-in approaches to tag endogenous TMEM179 with fluorescent proteins like mNeonGreen or HaloTag enable live-cell imaging of protein dynamics without antibody limitations. Super-resolution microscopy techniques including STORM, PALM, or lattice light-sheet microscopy provide nanoscale resolution of TMEM179 distribution within the endoplasmic reticulum , potentially revealing specialized subdomains or protein clusters. Proximity labeling methods such as BioID or APEX2, when fused to TMEM179, can identify neighboring proteins in the native cellular environment, providing insights into the protein's functional microenvironment. For studying protein dynamics, fluorescence recovery after photobleaching (FRAP) or photoactivation can measure TMEM179 mobility within membranes. Single-molecule tracking using quantum dots or other bright, photostable fluorophores conjugated to anti-TMEM179 antibodies or nanobodies can reveal molecular motion at unprecedented resolution. These advanced approaches, while technically demanding, offer potential breakthroughs in understanding the function of this poorly characterized transmembrane protein in neuronal systems.

How can researchers investigate potential roles of TMEM179 in neurological disorders?

Given TMEM179's suspected role in the nervous system , investigating its involvement in neurological disorders represents an important research frontier. Researchers should begin by analyzing TMEM179 expression in relevant patient-derived samples or disease models using validated antibodies. The Proteintech antibody (24799-1-AP), which has been used successfully in IHC applications , could be employed to examine expression patterns in post-mortem brain tissue from neurological disease patients compared to controls. Animal models of neurological conditions can be probed for alterations in TMEM179 expression, localization, or post-translational modifications. Functional studies using CRISPR-Cas9 knockout or knockdown approaches in neuronal cell cultures can reveal whether TMEM179 deficiency recapitulates disease-relevant phenotypes. Given TMEM179's ER localization , investigations into its potential role in ER stress responses—which are implicated in many neurodegenerative diseases—may be particularly insightful. Multi-omics approaches integrating proteomics, transcriptomics, and functional genomics could identify disease-associated pathways involving TMEM179. Finally, genetic association studies examining TMEM179 variants in patient cohorts with neurological disorders may reveal connections to specific clinical presentations or disease susceptibilities.

What technical advances are needed to better characterize TMEM179 protein interactions?

Despite being discovered years ago, TMEM179 protein interactions remain poorly characterized, highlighting the need for technical innovations in this area. Development of higher-affinity, more specific antibodies targeting different epitopes of TMEM179 would enable more robust immunoprecipitation studies. Monoclonal antibodies with defined epitopes or recombinant antibody fragments could provide improved specificity over the currently available polyclonal antibodies . Proximity labeling approaches such as TurboID or APEX2 fused to TMEM179 would allow identification of the protein's interactome in living cells without disrupting membrane integrity. Advanced structural biology techniques including cryo-electron microscopy of membrane protein complexes could reveal TMEM179's three-dimensional structure and interaction interfaces. For challenging membrane protein interactions, stabilization strategies such as nanodiscs or amphipols may preserve native-like environments during purification and analysis. Development of TMEM179-specific nanobodies would enable super-resolution imaging of protein complexes and potentially serve as crystallization chaperones for structural studies. These technical advances would significantly advance understanding of TMEM179's molecular functions by elucidating its protein interaction network within the endoplasmic reticulum and potentially other cellular compartments.